{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=63", "query": { "intervention": "ABI-007(Abraxane)", "page": 63 }, "page_size": 10 }, "pagination": { "page": 63, "page_size": 10, "total_count": 2451, "total_pages": 246, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=64&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=62&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T22:46:44.128Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06795009", "title": "Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Uterine Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "Zanzalintinib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 36, "start_date": "2025-10-17", "completion_date": "2035-04-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-24T22:46:44.128Z", "location_count": 4, "location_summary": "San Francisco, California • St Louis, Missouri • Albuquerque, New Mexico + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT06795009" }, { "nct_id": "NCT03932409", "title": "Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Vaginal cuff brachytherapy (VCB)", "type": "RADIATION" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 45, "start_date": "2020-02-19", "completion_date": "2027-06-25", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-24T22:46:44.128Z", "location_count": 2, "location_summary": "New Orleans, Louisiana • Oklahoma City, Oklahoma", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03932409" }, { "nct_id": "NCT00047632", "title": "Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Carcinoma", "Peritoneal Carcinoma" ], "interventions": [ { "name": "Interferon gamma-1b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InterMune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 847, "start_date": "2001-10", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2007-11-01", "last_synced_at": "2026-10-24T22:46:44.128Z", "location_count": 1, "location_summary": "Brisbane, California", "locations": [ { "city": "Brisbane", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00047632" }, { "nct_id": "NCT06264180", "title": "VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Melanoma" ], "interventions": [ { "name": "Vusolimogene Oderparepvec", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab + Relatlimab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Single-agent chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 400, "start_date": "2024-07-11", "completion_date": "2031-03-31", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-24T22:46:44.128Z", "location_count": 50, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 42 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06264180" }, { "nct_id": "NCT03981796", "title": "A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Dostarlimab", "type": "BIOLOGICAL" }, { "name": "Placebo matching dostarlimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Niraparib", "type": "DRUG" }, { "name": "Placebo matching Niraparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 785, "start_date": "2019-07-18", "completion_date": "2026-11-26", "has_results": false, "last_update_posted_date": "2025-09-03", "last_synced_at": "2026-10-24T22:46:44.128Z", "location_count": 59, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 49 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03981796" }, { "nct_id": "NCT06996782", "title": "A Platform Study in Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2025-11-24", "completion_date": "2029-02-23", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-24T22:46:44.128Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Santa Rosa, California • Jacksonville, Florida + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06996782" }, { "nct_id": "NCT00373217", "title": "Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine", "type": "BIOLOGICAL" }, { "name": "tetanus toxoid helper peptide", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 6, "start_date": "2006-04-13", "completion_date": "2008-02-07", "has_results": true, "last_update_posted_date": "2022-09-21", "last_synced_at": "2026-10-24T22:46:44.128Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00373217" }, { "nct_id": "NCT02905578", "title": "A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Neoplasms", "Cancer of Pancreas", "Cancer of the Pancreas", "Neoplasms, Pancreatic", "Pancreas Cancer", "Pancreas Neoplasms", "Adenocarcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Pharmacological ascorbate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-11-28", "completion_date": "2024-08-26", "has_results": true, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-24T22:46:44.128Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02905578" }, { "nct_id": "NCT01792050", "title": "Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Indoximod", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2013-02", "completion_date": "2017-07-07", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-10-24T22:46:44.128Z", "location_count": 28, "location_summary": "Gainesville, Florida • Tampa, Florida • Titusville, Florida + 24 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Titusville", "state": "Florida" }, { "city": "Weston", "state": "Florida" }, { "city": "Athens", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01792050" }, { "nct_id": "NCT00217724", "title": "Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pain", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "glutamine", "type": "DIETARY_SUPPLEMENT" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 18, "start_date": "1999-07", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-24T22:46:44.128Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00217724" } ] }